Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

Efficacy, Immunogenicity and Safety of Inactivated ERUCOV-VAC Compared With Placebo in COVID-19

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04824391
Recruitment Status : Recruiting
First Posted : April 1, 2021
Last Update Posted : April 1, 2021
TC Erciyes University
Information provided by (Responsible Party):
Health Institutes of Turkey

Brief Summary:
The objective is to determine the efficacy, immunogenicity and safety of two different strengths (3 µg and 6 µg) of an inactivated COVID 19 Vaccine compared to placebo so that to demonstrate the efficacy and safety in prophylaxis of COVID-19.

Condition or disease Intervention/treatment Phase
COVID-19 Biological: ERUCOV-VAC 3 µg/0.5 ml Vaccine Biological: ERUCOV-VAC 6 µg/0.5 ml Vaccine Other: Placebo Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 250 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Prevention
Official Title: Phase 2 Study for the Determination of Efficacy, Immunogenicity and Safety of Two Different Strengths of the Inactivated COVID-19 Vaccine ERUCOV-VAC, in a Placebo Controlled, Randomized, Double Blind Study Design.
Actual Study Start Date : February 10, 2021
Estimated Primary Completion Date : April 30, 2021
Estimated Study Completion Date : April 30, 2022

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: 3 mcg/0.5 ml Vaccine
Low dose vaccine
Biological: ERUCOV-VAC 3 µg/0.5 ml Vaccine
Two IM applications on Days 1 and 28

Experimental: 6 mcg/0.5 ml Vaccine
Medium dose vaccine
Biological: ERUCOV-VAC 6 µg/0.5 ml Vaccine
Two IM applications on Days 1 and 28

Placebo Comparator: Placebo
Other: Placebo
Two IM applications on Days 1 and 28

Primary Outcome Measures :
  1. Serum IgG antibody levels specific for the SARS-CoV- 2 rS protein antigen(s) [ Time Frame: 12 months ]
  2. Neutralizing antibodies from microneutralization assay [ Time Frame: 12 months ]
  3. Blood levels of cytokines: TNF-α, IFN-γ, IL-2, IL-4, IL-5 and IL-6 [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Adverse events [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 64 Years   (Adult)
Sexes Eligible for Study:   All
Gender Based Eligibility:   Yes
Gender Eligibility Description:   Non-pregnant women
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • healthy Caucasian origin
  • accepting not to participate in another COVID-19 vaccine study until the end of the study
  • volunteers who do not plan to get a child in the next one year; the volunteer and the partner should use a reliable form of contraception (abstinence, condom, birth control implant, birth control pills used or IUD used by the partner) during the study for at least 1 year
  • female participants of childbearing potential (defined as any female who has experienced menarche and who is NOT surgically sterile [ie, hysterectomy, bilateral tubal ligation, or bilateral oophorectomy] or postmenopausal [defined as amenorrhea at least 12 consecutive months) must agree to be heterosexually inactive through 12 months after the first vaccination OR agree to consistently use any of the described methods of contraception from through 12 months after the first vaccination.
  • male subjects agree to refrain from sperm donation from the time of first vaccination until 3 months after last vaccination
  • participants must refrain from blood or plasma donation from the time of first vaccination until 3 months after last vaccination
  • the outcome of the following examinations should be clinically insignificant: medical and surgical history (hypo-, hypertension, allergy, other diseases, major surgery, micturition, defecation, sleep, illness within the last 4 weeks prior to the start of the trial);
  • life style and habits (consumption of alcohol, nicotine, coffee, tea, coke, special diet, drug abuse) should be normal/acceptable
  • body temperature, pulse rate, blood pressure and respiratory rate should be normal/acceptable.
  • laboratory examination (blood/serum examination: sodium, potassium, calcium, total protein, albumin, glucose, creatinine, BUN, total bilirubin, AST, ALT, GGT, ALP, haemoglobin, haematocrit, erythrocytes, Ieukocytes, platelet count; HBsAg, HIV-Ab, HCV-Ab should be normal/acceptable.
  • antiSARS CoV 2 total antibody (including COVID-19 IgG and/or IgM) negative in serum.
  • body weight in relation to height and age accepted BMI range 18.5 and 32 kg/m2 - both inclusive

Exclusion Criteria:

  • women with a positive blood (β-HCG) pregnancy test
  • lactating women
  • history of COVID-19 infection or showing COVID-19 infection symptoms
  • having had contact to people with known COVID-19 infection in the last 14 days
  • having fever (> 37.4oC in the last 24 hours), dry cough or feeling tired and having aches and pains, nasal congestion, runny nose, sore throat and diarrhea.
  • positive real time RT-PCR COVID-19 test.
  • leukemia or neoplasm in history.
  • persons with autoimmune diseases
  • allergic diathesis or any clinically significant allergic disease (i.e. asthma)
  • any condition that might impair the immune response
  • recent or current immunosuppressive medication
  • any other vaccine application 30 days before the first dose
  • presence or a history of clinically significant cardiovascular, renal, hepatic, pulmonary, metabolic, endocrine, haematological, gastrointestinal, neurological, psychiatric or other major diseases;
  • disruption of platelets or other blood clotting disorders, which may cause contraindications to intramuscular administration
  • clinically significant illness within 4 weeks before the start of the study. Especially any acute or chronic illness seizures.
  • any regular intake or administration of any prescribed systemic or topical medication within 2 weeks prior to the start of the study; in the case of intake or administration of any prescribed systemic or topical medication within 4 weeks before the start of the study because of an insignificant illness, this should be stated in the CRF.
  • intake or administration of OTC medication (including herbal remedies) which may have an effect on the study according to the investigator within 2 weeks prior to the start of the study
  • volunteers who received antiviral drugs, immunoglobulins or blood transfusions or any other investigational drug within 4 weeks prior to the first study product administration
  • concomitant intake or administration of any systemic or topical drugs (including herbal remedies) on the application days
  • treatment with any investigational drug (i.e., drug not yet approved) in the last 4 weeks before beginning of the trial
  • medication with drugs known to alter organs or systems such as barbiturates, phenothiazines, cimetidine, omeprazole etc. within the last 1 month (4 weeks)
  • donation of blood or plasma more than 450 ml within the last 2 months (8 weeks) or any amount within the last month (4 weeks)
  • supine blood pressure, after resting for 5 min, higher than 140/90 or lower than 100/60 mmHg
  • supine pulse rate, after resting for 5 min, outside the range of 50 - 100 beats/min
  • supine respiratory rate, after resting for 5 min, outside the range of 15 - 18 breathings / min
  • laboratory values (appendix 5) outside normal range with clinical relevance at entry examination
  • alcohol abuse i.e. regular use of more than 2 units of alcohol per day or a history of alcoholism or drug/chemical abuse (one unit of alcohol equals ½ l of beer, 200 ml wine or 50 ml of spirits) or recovered alcoholics
  • caffeine abuse i.e. regular use of more than 750 mg/day caffeine
  • alcoholic or methylxanthine-containing beverages or foods (coffee, tea, coke, chocolate) and fruit-juice from 24 hours prior to each application
  • smoking of more than 10 cigarettes or equivalent per day, no smoking before application
  • vegetarian or any special diet due to any reason
  • knowledge to have any type of parenterally transmitted hepatitis or carrier of the HBsAg (HBsAg test positive)
  • HIV-Ab test positive
  • Test on anti-HCV antibodies positive
  • legal incapacity and/or other circumstances rendering the subject unable to understand the nature, scope and possible consequences of the study
  • evidence of an uncooperative attitude.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT04824391

Layout table for location contacts
Contact: Gamze Kalin Unuvar, Assist.Prof. 00905359872894

Layout table for location information
Erciyes University Recruiting
Kayseri, Turkey, 38039
Contact: Zafer Sezer, Assoc.Prof.    00903524374429   
Sub-Investigator: Ahmet Inal, Assist.Prof.         
Sub-Investigator: Mumtaz Mazicioglu, Prof.         
Sub-Investigator: Adnan Bayram, Prof.         
Sub-Investigator: Zeynep Ture Yuce, Assist.Prof.         
Sponsors and Collaborators
Health Institutes of Turkey
TC Erciyes University
Layout table for investigator information
Study Director: Zafer Sezer, Assoc.Prof. Co-Investigator
Layout table for additonal information
Responsible Party: Health Institutes of Turkey Identifier: NCT04824391    
Other Study ID Numbers: IDEAL00620-EU02-PK537-3
First Posted: April 1, 2021    Key Record Dates
Last Update Posted: April 1, 2021
Last Verified: March 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Health Institutes of Turkey:
Phase 2
Additional relevant MeSH terms:
Layout table for MeSH terms
Respiratory Tract Infections
Pneumonia, Viral
Virus Diseases
Coronavirus Infections
Coronaviridae Infections
Nidovirales Infections
RNA Virus Infections
Lung Diseases
Respiratory Tract Diseases
Immunologic Factors
Physiological Effects of Drugs